In order to verify suitability of the newly created method for the CTSL quantification in biological samples, two types of the samples by the SPRI biosensor and ELISA were analyzed: nine control blood plasma samples and nine blood plasma samples of the patients collected before and after the surgical resection: ovarian tumor, ovarian cyst or gall bladder removal. The gene discussed is CTSL; the disease is medical procedure.